PAIN
Volume 90, Issue 3 , Pages 205-215 , 15 February 2001

Response variability to analgesics: a role for non-specific activation of endogenous opioids

  • Martina Amanzio

      Affiliations

    • Department of Neuroscience, University of Torino Medical School, Corso Raffaello 30, 10125 Torino, Italy
    • ,
  • Antonella Pollo

      Affiliations

    • Department of Neuroscience, University of Torino Medical School, Corso Raffaello 30, 10125 Torino, Italy
    • ,
  • Giuliano Maggi

      Affiliations

    • Division of Thoracic Surgery, University of Torino, 10126 Torino, Italy
    • ,
  • Fabrizio Benedetti

      Affiliations

    • Department of Neuroscience, University of Torino Medical School, Corso Raffaello 30, 10125 Torino, Italy
    • Rita Levi-Montalcini Center for Brain Repair, University of Torino, 10125 Torino, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-011-6707709; fax: +39-011-6707708

Received 23 October 2000 ,Revised 7 December 2000 ,Accepted 12 December 2000.

References 

  1. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999;19:484–494
  2. Arnér S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1988;33:11–23
  3. Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain. 1996;64:535–543
  4. Benedetti F. Cholecystokinin type A and type B receptors and their modulation of opioid analgesia. News Physiol Sci. 1997;12:263–268
  5. Benedetti F, Amanzio M, Baldi S, Casadio C, Maggi G. Inducing placebo respiratory depressant responses in humans via opioid receptors. Eur J Neurosci. 1999;11:625–631
  6. Benedetti F, Arduino C, Amanzio M. Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci. 1999;19:3639–3648
  7. Benedetti F, Vighetti S, Amanzio M, Casadio C, Oliaro A, Bergamasco B, et al. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain. 1998;74:205–211
  8. Dickenson AH. Neurophysiology of opioid poorly responsive pain. Cancer Surv. 1994;21:5–16
  9. El-Sobky A, Dostrovsky JO, Wall PD. Lack of effect of naloxone on pain perception in humans. Nature. 1976;263:783–784
  10. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD. Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med. 1996;2:1248–1250
  11. Gracely RH, Dubner R, Wolskee PJ, Deeter WR. Placebo and naloxone can alter postsurgical pain by separate mechanisms. Nature. 1983;306:264–265
  12. Grevert P, Goldstein A. Effects of naloxone on experimentally induced ischemic pain and on mood in human subjects. Proc Natl Acad Sci USA. 1977;74:1291–1294
  13. Grevert P, Goldstein A. Endorphins: naloxone fails to alter experimental pain or mood in humans. Science. 1978;199:1093–1095
  14. Grevert P, Albert LH, Goldstein A. Partial antagonism of placebo analgesia by naloxone. Pain. 1983;16:129–143
  15. Harrington A. The placebo effect. An interdisciplinary exploration. Cambridge, MA: Harvard University Press; 1997;
  16. Kaiko RF, Wallenstein SL, Rogers AG, Grabinski PY, Houde RW. Narcotics in the elderly. Med Clin North Am. 1982;66:1079–1089
  17. Lasagna L. Drug interaction in the field of analgesic drugs. Proc R Soc Med. 1965;58:978–983
  18. Levine JD, Gordon NC. Influence of the method of drug administration on analgesic response. Nature. 1984;312:755–756
  19. Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet. 1978;2:654–657
  20. Levine JD, Gordon NC, Fields HL. Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain. Nature. 1979;278:740–741
  21. Miller S. Experimental design and statistics. London: Methuen; 1984;
  22. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol. 1993;16:1–18
  23. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain. 1990;43:273–286
  24. Price DD. Factors that determine the magnitude and presence of placebo analgesia. In:  Devor M,  Rowbotham MC,  Wiesenfeld-Hallin Z editor. Proceedings of the 9th World Congress of Pain. Seattle, WA: IASP Press; 2000;p. 1085–1095
  25. Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain. 1999;83:147–156
  26. Schmauss C, Yaksh TL. In vivo studies on spinal opiate receptor systems mediating antinociception: II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral, chemical and cutaneous stimuli in the rat. J Pharmacol Exp Ther. 1983;228:1–12
  27. Smith GM, Egbert LD, Markowitz RA, Mosteller F, Beecher HK. An experimental pain method sensitive to morphine in man: the submaximum effort tourniquet technique. J Pharmacol Exp Ther. 1966;154:324–332
  28. Smith GM, Lowenstein E, Hubbard JH, Beecher HK. Experimental pain produced by the submaximum effort tourniquet technique: further evidence of validity. J Pharmacol Exp Ther. 1972;163:468–474
  29. Volavka J, Bauman J, Pevnick J, Reker D, James B, Cho D. Short-term hormonal effects of naloxone in man. Psychoneuroendocrinology. 1980;5:225–234
  30. White L, Tursky B, Schwartz GE. Placebo: theory, research, and mechanisms. New York: Guilford Press; 1985;
  31. Wiesenfeld-Hallin Z, Alster P, Grass S, Hoffmann O, Lucas GA, Plesan A, et al. Opioid sensitivity in antinociception: role of anti-opioid systems with emphasis on cholecystokinin and NMDA receptors. In:  McQuay HJ,  Wiesenfeld-Hallin Z editor. Opioid sensitivity of chronic non-cancer pain. Seattle, WA: IASP Press; 1999;p. 237–252

PII: S0304-3959(00)00486-3

PAIN
Volume 90, Issue 3 , Pages 205-215 , 15 February 2001

Article Tools

* Image Usage & Resolution